Viiv Lies about m184v and taf

Quote






anonymous said:
Go on then.
Click to expand...
Boring... nothing better to do than point fingers. Gilead lies to their reps, manipulates doctors and twists research around. You all drink this cool aid. It is sickening. You will all be screwed over eventually once you say the wrong thing to the wring person. They’ll just find a reason to get you fired - after years of loyalty! Watch your back and run !
 












On March 2019, an antiretroviral-experienced HIV-infected patient was admitted to hospital because of cerebral toxoplasmosis. After undergoing treatment with sulfadiazine-pyrimethamine for two weeks, the patient initiated a BIC/FTC/TAF treatment, with 6.01 HIV RNA Log copies/mL, and 37 CD4 cells/μL. After two months under antiretroviral therapy (ART), acute neurologic deterioration with epilepsy, right hemiparesis and dysphagia occurred, leading to nasogastric nutrition and treatment. After several weeks, virological failure was confirmed with 4.01 HIV RNA Log copies/mL and R263K and M184V resistance mutations were detected.

Now, at least 3 cases of BIKTARVY failures, multi drug class resistance and so go the lies. This will catch up to Gilead and a magical new drug will come out just like the TAF replacements for TDF.

Now, TAF is causing issues and the academic centers are trying to figure out what to do- go back to TDF switch to hmmm lets see what 2021 brings.
 






anonymous said:
On March 2019, an antiretroviral-experienced HIV-infected patient was admitted to hospital because of cerebral toxoplasmosis. After undergoing treatment with sulfadiazine-pyrimethamine for two weeks, the patient initiated a BIC/FTC/TAF treatment, with 6.01 HIV RNA Log copies/mL, and 37 CD4 cells/μL. After two months under antiretroviral therapy (ART), acute neurologic deterioration with epilepsy, right hemiparesis and dysphagia occurred, leading to nasogastric nutrition and treatment. After several weeks, virological failure was confirmed with 4.01 HIV RNA Log copies/mL and R263K and M184V resistance mutations were detected.

Now, at least 3 cases of BIKTARVY failures, multi drug class resistance and so go the lies. This will catch up to Gilead and a magical new drug will come out just like the TAF replacements for TDF.

Now, TAF is causing issues and the academic centers are trying to figure out what to do- go back to TDF switch to hmmm lets see what 2021 brings.
Click to expand...

false and false. The academic centers are using Biktarvy as standard of care to end the epidemic. Viiv and it’s band of bad actors are busy conspiring on how to position a horrible drug in a time that it offers no value to patients and current market. I feel bad for Viiv.. the I listen to them and don’t anymore.
 






anonymous said:
false and false. The academic centers are using Biktarvy as standard of care to end the epidemic. Viiv and it’s band of bad actors are busy conspiring on how to position a horrible drug in a time that it offers no value to patients and current market. I feel bad for Viiv.. the I listen to them and don’t anymore.
Click to expand...


I’m just glad that Dimitri on the ad is doing well so he can kiss his lover and not worry about sharing his “wealth” when they get freaky afterwards.
 












anonymous said:
On March 2019, an antiretroviral-experienced HIV-infected patient was admitted to hospital because of cerebral toxoplasmosis. After undergoing treatment with sulfadiazine-pyrimethamine for two weeks, the patient initiated a BIC/FTC/TAF treatment, with 6.01 HIV RNA Log copies/mL, and 37 CD4 cells/μL. After two months under antiretroviral therapy (ART), acute neurologic deterioration with epilepsy, right hemiparesis and dysphagia occurred, leading to nasogastric nutrition and treatment. After several weeks, virological failure was confirmed with 4.01 HIV RNA Log copies/mL and R263K and M184V resistance mutations were detected.

Now, at least 3 cases of BIKTARVY failures, multi drug class resistance and so go the lies. This will catch up to Gilead and a magical new drug will come out just like the TAF replacements for TDF.

Now, TAF is causing issues and the academic centers are trying to figure out what to do- go back to TDF switch to hmmm lets see what 2021 brings.
Click to expand...

Fortunately for them, ViiV launched a new “Standard of Care” a couple years ago in Dovato. According to ViiV, this would have been an ideal option. I wonder why, outside of ViiV, nobody is using “the new gold standard?”
 






Have you seen the new “Blip-tarvy” data it’s catching the attention of doctors across the country- oh wait there is no data it is just happening to everyone across the country. Now doctors understand why you launch with minimal perfect scenario data - worthless 2 years after real world
 






anonymous said:
Fortunately for them, ViiV launched a new “Standard of Care” a couple years ago in Dovato. According to ViiV, this would have been an ideal option. I wonder why, outside of ViiV, nobody is using “the new gold standard?”
Click to expand...
Not sure why any HIV drug has to be a gold standard. There are MANY good options- doctors are learning what happens when you over prescribe “Blip-tarvy” coming to conferences across the nation
 






anonymous said:
Not sure why any HIV drug has to be a gold standard. There are MANY good options- doctors are learning what happens when you over prescribe “Blip-tarvy” coming to conferences across the nation
Click to expand...

this constant mudslinging is either a former gilead rep who got stuck at Viiv from being canned or a wacko troll that can’t read a package insert. Biktarvy is used for most patients. Good on dovato for finding less than 1% who would qualify and even those would be better off not worrying about lamividine. 3tc is an old dog that will fail from any adherence issue and even then it still might.
 






anonymous said:
this constant mudslinging is either a former gilead rep who got stuck at Viiv from being canned or a wacko troll that can’t read a package insert. Biktarvy is used for most patients. Good on dovato for finding less than 1% who would qualify and even those would be better off not worrying about lamividine. 3tc is an old dog that will fail from any adherence issue and even then it still might.
Click to expand...
Tell that you to the research- what evidence so you have ? Old unpaired evidence? Tell that to the FDA and real world evidence that shows proof otherwise. And while you’re at it go look up the 3 patients and counting that failed Biktarvy with your BIk signature mutation r263 and all with M184v

so fuck you lying piece of shit troll. The world is about to hate Gilead for lying about data, overcharging for drugs and the corrupt bullshit that just happened with Remdesvir in China. The truth will all come out, watch and learn.
 






anonymous said:
this constant mudslinging is either a former gilead rep who got stuck at Viiv from being canned or a wacko troll that can’t read a package insert. Biktarvy is used for most patients. Good on dovato for finding less than 1% who would qualify and even those would be better off not worrying about lamividine. 3tc is an old dog that will fail from any adherence issue and even then it still might.
Click to expand...
Haven’t actually seen this 3TC adherence issue to be true. Have heard a lot of bullshit data beinf shared by gilead about other companies, slinging mud around to confuse providers. If adherence were an issue any drug would fail. Biktarvy has blips and failures and isn’t that wonderful. So long Blip-tarvy
 






anonymous said:
Fortunately for them, ViiV launched a new “Standard of Care” a couple years ago in Dovato. According to ViiV, this would have been an ideal option. I wonder why, outside of ViiV, nobody is using “the new gold standard?”
Click to expand...
Yes - so strange only ViiV and the idiot on here digging Biktarvy get this - strange
 






Any infectious disease hcp doesn’t fall for this mess. Biktarvy is a game changer and has proven so. It will be the standard for years to come until a safe, long term pill or injectable is feasible and subQ. Until then Viiv products will peak at a few market share points. If you don’t think adherence is an issue you don’t work in HIV and if you don’t think lamivudine is a problem, you aren’t in present year. There is a reason Viiv trials screened for m184v and cherry picked patients. If you worry about cost, then why does Viiv charge full commercial cost for 3tc when it’s actually generic? I’ll answer. Viiv is not a market leader and does what small guys do to stay in business..they aren’t even allowed in most offices from desperation and poor representation of product.
 






anonymous said:
Any infectious disease hcp doesn’t fall for this mess. Biktarvy is a game changer and has proven so. It will be the standard for years to come until a safe, long term pill or injectable is feasible and subQ. Until then Viiv products will peak at a few market share points. If you don’t think adherence is an issue you don’t work in HIV and if you don’t think lamivudine is a problem, you aren’t in present year. There is a reason Viiv trials screened for m184v and cherry picked patients. If you worry about cost, then why does Viiv charge full commercial cost for 3tc when it’s actually generic? I’ll answer. Viiv is not a market leader and does what small guys do to stay in business..they aren’t even allowed in most offices from desperation and poor representation of product.
Click to expand...
#idiotsdrinkingthecoolaid#gileadliars#BLIPTARVYSUCKS I can’t read anything you write anymore bla bla bla
btw had lunch with 5 offices this week in person so shove your lies up your ass
 












anonymous said:
#idiotsdrinkingthecoolaid#gileadliars#BLIPTARVYSUCKS I can’t read anything you write anymore bla bla bla
btw had lunch with 5 offices this week in person so shove your lies up your ass
Click to expand...
“Had five lunches this week and surged my 2 year old “standard of care” product Dovato to a 2% market share.” I’m sure those offices all laughed at your snake oil once you left, like we all do.
 


















Top Bottom
Back
Quote